Azeliragon

DB12689InvestigationalSmall molecule

Azeliragon has been used in trials studying the treatment of Alzheimer's Disease.

Mechanism: Pharmacologically active on Advanced glycation end product-specific receptor
Curator reviewed
Formula / weight: C₃₂H₃₈ClN₃O₂ · 532.13 g/mol (avg)
Code names: PF-04494700 · TTP488

Resolves to

Compound

Structure

InChIKeyKJNNWYBAOPXVJY-UHFFFAOYSA-NSMILESCCCCC1=NC(=CN1C1=CC=C(OC2=CC=C(Cl)C=C2)C=C1)C1=CC=C(OCCCN(CC)CC)C=C1

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

16Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Azeliragon, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.